CN101405293B - 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法 - Google Patents

天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法 Download PDF

Info

Publication number
CN101405293B
CN101405293B CN200680051907.4A CN200680051907A CN101405293B CN 101405293 B CN101405293 B CN 101405293B CN 200680051907 A CN200680051907 A CN 200680051907A CN 101405293 B CN101405293 B CN 101405293B
Authority
CN
China
Prior art keywords
compound
group
formula
carbon atoms
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200680051907.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101405293A (zh
Inventor
G·米洛特
S·布兰乔德
B·R·斯特瑞克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taimed Biologics Inc
Original Assignee
Ambrilia Biopharma Inc
Taimed Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrilia Biopharma Inc, Taimed Biologics Inc filed Critical Ambrilia Biopharma Inc
Publication of CN101405293A publication Critical patent/CN101405293A/zh
Application granted granted Critical
Publication of CN101405293B publication Critical patent/CN101405293B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200680051907.4A 2005-11-30 2006-11-30 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法 Expired - Fee Related CN101405293B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74064205P 2005-11-30 2005-11-30
US60/740,642 2005-11-30
PCT/CA2006/001963 WO2007062526A1 (en) 2005-11-30 2006-11-30 Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation

Publications (2)

Publication Number Publication Date
CN101405293A CN101405293A (zh) 2009-04-08
CN101405293B true CN101405293B (zh) 2013-03-13

Family

ID=38091843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200680051907.4A Expired - Fee Related CN101405293B (zh) 2005-11-30 2006-11-30 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法

Country Status (8)

Country Link
US (2) US8227450B2 (enExample)
EP (1) EP1971615B1 (enExample)
JP (1) JP2009517412A (enExample)
CN (1) CN101405293B (enExample)
AU (1) AU2006319716B2 (enExample)
CA (1) CA2632095A1 (enExample)
ES (1) ES2452718T3 (enExample)
WO (1) WO2007062526A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
WO2007062526A1 (en) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
AU2007287353A1 (en) * 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
ES2628730T3 (es) 2006-09-21 2017-08-03 Taimed Biologics, Inc. Inhibidores de proteasa
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10369129B2 (en) 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor
JP6704058B2 (ja) * 2016-05-31 2020-06-03 タイメド・バイオロジクス・インコーポレイテッドＴａｉＭｅｄ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． プロテアーゼ阻害剤の長時間作用性医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013861A (en) * 1985-02-28 1991-05-07 E. R. Squibb & Sons, Inc. Ester substituted aminoalkanoylureido amino and imino acid and ester compounds
CA2089747A1 (en) 1990-10-11 1992-04-12 Gerd Schnorrenberg Cyclopeptides, a method of preparing them, and their use as drugs
US5614522A (en) * 1990-11-19 1997-03-25 G.D. Searle & Co. Retroviral protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
ATE161828T1 (de) * 1992-08-25 1998-01-15 Searle & Co Sulfonylalkanoylaminohydroxyethylaminosulfonami e verwendbar als retrovirale protease-inhibitoren
US6022994A (en) * 1992-08-25 2000-02-08 G. D. Searle &. Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
CA2142998C (en) * 1992-08-25 2008-01-29 Michael L. Vazquez N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
JPH06321950A (ja) 1993-05-14 1994-11-22 Takeda Chem Ind Ltd 水溶性ランカシジン誘導体
AU6548294A (en) 1993-08-31 1995-03-22 Stanley Kugell Telephone billing method
MX9603909A (es) 1994-03-07 1997-03-29 Vertex Pharma Derivados de sulfonamida como inhibidores de proteasa aspartilo.
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE69637380T2 (de) * 1995-01-20 2009-09-17 G.D. Searle Llc, Chicago Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
US5985870A (en) * 1995-03-10 1999-11-16 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
WO1997027180A1 (en) 1996-01-26 1997-07-31 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
AU720615B2 (en) 1997-01-17 2000-06-08 Pharmacia & Upjohn Company Bis-sulfonomides hydroxamic acids as MMP inhibitors
ATE210639T1 (de) * 1997-05-09 2001-12-15 Hoechst Ag Substituierte diaminocarbonsäuren
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EP1042280A2 (en) * 1997-12-24 2000-10-11 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US5986102A (en) 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
EP1159278B1 (en) 1999-02-12 2005-11-30 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
CA2375511A1 (en) * 1999-06-16 2000-12-21 Temple University - Of The Commonwealth System Of Higher Education (z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
US6455587B1 (en) * 2000-03-15 2002-09-24 Pharmacor Inc. Amino acid derivatives as HIV aspartyl protease inhibitors
US6506786B2 (en) * 2001-02-13 2003-01-14 Pharmacor Inc. HIV protease inhibitors based on amino acid derivatives
JP4283681B2 (ja) 2002-03-04 2009-06-24 アンブリリア バイオファーマ インコーポレーテッド Ｈｉｖアスパルチルプロテアーゼ阻害剤としての尿素誘導体
CA2374362C (en) * 2002-03-04 2008-01-22 Brent Richard Stranix Urea derivatives as hiv aspartyl protease inhibitors
KR20050085681A (ko) 2002-12-16 2005-08-29 베링거 인겔하임 인터내셔날 게엠베하 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도
DE602004024584D1 (de) 2004-01-08 2010-01-21 Medivir Ab Inhibitoren der nicht-nukleotidischen reversen transkriptase
EP2165709B1 (en) * 2004-08-02 2016-03-16 Ambrilia Biopharma Inc. Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
US20060287316A1 (en) * 2005-04-27 2006-12-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
WO2007062526A1 (en) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
AU2007287353A1 (en) 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
ES2628730T3 (es) 2006-09-21 2017-08-03 Taimed Biologics, Inc. Inhibidores de proteasa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李宗韦.STN检索报告.《STN检索报告》.2010, *

Also Published As

Publication number Publication date
WO2007062526A8 (en) 2007-08-30
AU2006319716A1 (en) 2007-06-07
CA2632095A1 (en) 2007-06-07
AU2006319716B2 (en) 2012-02-02
US8227450B2 (en) 2012-07-24
EP1971615A4 (en) 2011-06-22
CN101405293A (zh) 2009-04-08
WO2007062526A1 (en) 2007-06-07
ES2452718T3 (es) 2014-04-02
US20090253926A1 (en) 2009-10-08
EP1971615B1 (en) 2014-01-01
EP1971615A1 (en) 2008-09-24
US20100130765A1 (en) 2010-05-27
HK1124861A1 (en) 2009-07-24
US8580995B2 (en) 2013-11-12
JP2009517412A (ja) 2009-04-30

Similar Documents

Publication Publication Date Title
US8580995B2 (en) Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
US8008297B2 (en) Lysine based compounds
AP1172A (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors.
US20120053139A1 (en) Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
AU2009230800A1 (en) Lysine based compounds
CA2657316A1 (en) Method for improving pharmacokinetics
HK1124861B (en) Lysme-based prodrugs of aspartyl protease inhibitors and processes for their preparation
RU2379312C2 (ru) Соединения на основе лизина, фармацевтическая композиция, содержащая эти соединения, применение указанных соединений для лечения или профилактики вич инфекции
CN102093411A (zh) 基于赖氨酸的化合物
ZA200607352B (en) Lysine based compounds
HK1105406B (en) Lysine based compounds
NZ552853A (en) Lysine based compounds
KR20070057815A (ko) 리신계 화합물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: TAIMED BIOLOGICS

Free format text: FORMER OWNER: AMBRILIA BIOPHARMA INC.

Effective date: 20130128

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; TO: TAIWAN, CHINA

TA01 Transfer of patent application right

Effective date of registration: 20130128

Address after: Taiwan, China

Applicant after: Taimed Biologics, Inc.

Address before: Quebec

Applicant before: Ambrilia Biopharma Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130313

Termination date: 20201130

CF01 Termination of patent right due to non-payment of annual fee